These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15604941)

  • 21. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
    Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
    J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-risk papillary thyroid cancer recurrence in patients treated with total thyroidectomy and adjuvant therapy vs. patients treated with partial thyroidectomy.
    Hurtado-López LM; Melchor-Ruan J; Basurto-Kuba E; Montes de Oca-Durán ER; Pulido-Cejudo A; Athié-Gutiérrez C
    Cir Cir; 2011; 79(2):118-25. PubMed ID: 21631972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
    Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer.
    Salvatori M; Rufini V; Reale F; Samanes Gajate AM; Maussier ML; Revelli L; Troncone L; Ardito G
    World J Surg; 2003 Jul; 27(7):770-5. PubMed ID: 14509503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
    Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
    World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of patients to detect recurrent thyroid carcinoma.
    Grigsby PW; Baglan K; Siegel BA
    Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
    Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
    Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?
    Hindié E; Zanotti-Fregonara P; Duron F; Keller I; Bouchard P; Devaux JY
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):329-34. PubMed ID: 17302864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Video-assisted thyroidectomy for papillary thyroid carcinoma.
    Bellantone R; Lombardi CP; Raffaelli M; Alesina PF; De Crea C; Traini E; Salvatori M
    Surg Endosc; 2003 Oct; 17(10):1604-8. PubMed ID: 12874681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival of patients with papillary thyroid cancer after surgical microdissection.
    Tisell LE; Nilsson B; Mölne J; Hansson G; Fjälling M; Jansson S; Wingren U
    World J Surg; 1996 Sep; 20(7):854-9. PubMed ID: 8678962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.
    Schmidt D; Linke R; Uder M; Kuwert T
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):699-705. PubMed ID: 19936746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of total thyroidectomy for differentiated thyroid carcinoma: a 20-year review.
    Ley PB; Roberts JW; Symmonds RE; Hendricks JC; Snyder SK; Frazee RC; Smith RW; McKenney JF; Brindley GV
    Am Surg; 1993 Feb; 59(2):110-4. PubMed ID: 8476139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.